Jazz Pharmaceuticals

Summary

(Learn how and when to remove this template message)
Jazz Pharmaceuticals plc
TypePublic company
IndustryBiotechnology
Pharmaceutical
PredecessorJazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
FoundedMarch 2005; 16 years ago (2005-03) in California, U.S.
HeadquartersWaterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland
Area served
Worldwide
Key people
Bruce C. Cozadd
(Chairman & CEO)
ProductsPharmaceutical drugs
Brands
RevenueIncrease US$1.618 billion (2017)[1]
Decrease US$528.8 million (2017)[1]
Increase US$487.8 million (2017)[1]
Total assetsIncrease US$5.123 billion (2017)[1]
Total equityIncrease US$2.713 billion (2017)[1]
Number of employees
~1,210 (February 2018)[1]
Websitejazzpharma.com

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA).

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

Company history and acquisitions

2010–2019

On February 18, 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia.[5] In the following December, a new patent was issued for Sodium Oxybate.[6]

On September 19, 2011, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.[7]

On April 26, 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments).[8] In September, the company successfully sold its Women's Health business to Meda for $95 million.[9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.[10]

In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.[11][12]

In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.[15]

In August 2019, the company announced it would acquire Cavion Inc. for up to ~$310 million.[16][17]

2020 onwards

In January 2021, Jazz announced it would acquire GW Pharmaceuticals for $7.2 billion ($200.00 in cash and $20.00 in shares of Jazz).[18][19]

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Jazz Pharmaceuticals
(Merged 2011)

Jazz Pharmaceuticals

Azur Pharma PLC

EUSA Pharma
(Acq 2012)

Gentium SpA
(Acq 2014)

Alizé Pharma II
(Acq 2016)

Celator Pharmaceuticals
(Acq 2016)

Cavion Inc.
(Acq 2019)

References

  1. ^ a b c d e f g "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018.
  2. ^ "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
  3. ^ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
  4. ^ "Teva wins controversial PhRMA bid despite protests from branded rivals".
  5. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  6. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  7. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  8. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  9. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  10. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  11. ^ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
  12. ^ "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News (paper) |format= requires |url= (help). 34 (2). January 15, 2014. p. 10.
  13. ^ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
  14. ^ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN". 31 May 2016.
  15. ^ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.
  16. ^ "Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc".
  17. ^ "Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc. | Jazz Pharmaceuticals PLC".
  18. ^ "Jazz Pharmaceuticals to Acquire GW Pharmaceuticals PLC, Creating an Innovative, High-Growth, Global Biopharma Leader".
  19. ^ Reuters[dead link][bare URL]